Skip to content
Communicating Drug Interaction and QTc Information in the U.S. Prescribing Information

Communicating Drug Interaction and QTc Information
in the U.S. Prescribing Information
September 23, 2026

View Start Time on World Clock

The first session of this webinar will discuss the draft guidance for industry: Drug Interaction Information in Human Prescription Drug and Biological Product Labeling (October 2024). Topics include:

  • DRUG INTERACTIONS section:
    • Organization and format
    • Required and recommended elements
    • Instructions for preventing or managing clinically significant drug interactions
    • Mechanisms of clinically significant drug interactions
    • Clinical effects of clinically significant drug interactions
    • Recommendations on including drug interacting class information
    • Information to avoid in the DRUG INTERACTIONS section
    • Drug interactions information in other sections of labeling (e.g., BOXED WARNING, DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, CLINICAL PHARMACOLOGY sections)

The second session of this webinar will discuss the guidance for industry:QTc Information in Human Prescription Drug and Biological Product Labeling (December 2025). Topics include:

  • Risk factors for and clinical consequences of QTc interval prolongation
  • Assessment of the QTc interval during drug development
  • Including QTc interval information in the CLINICAL PHARMACOLOGY section when there is:
    • Clinically significant QTc interval prolongation
    • No clinically significant QTc interval prolongation
    • Insufficient data to characterize the risk
  • Including QTc interval information in the DRUG INTERACTIONS section when the use of the subject drug with other products:
    • That are known or suspected to prolong the QTc interval
    • Increase the concentration of the subject drug (when there is a concentration-dependent QTc interval prolongation.

Click Here for Details

PDF Download
Event Agenda

The event agenda is still being refined and will be posted when it is complete.

PDF Download
Speaker Biographies

The speaker biographies document provides detailed information for each of the event presenters.

Ability to submit questions
Cannot pause or rewind
Limited to 1,000 seats
Use Login Two if this room is full

Ability to pause or rewind
Cannot submit live questions
Unlimited Seating

Use this if you encounter issues
with the other links
Your attendance will NOT
be tracked in our system

The above rooms will open ~15 minutes before each day begins.

If you encounter any technical issues, visit the Technical Issues Support Page

Download Presentation Slides

A link for you to download the presentation slides will be added here when they are available.

Event Evaluation & Certificate

A link for you to evaluate the Event and access the online certificate will be added here on the second afternoon of the event.

Session Recordings

Recordings will be linked here as soon as they are available.

Continuing Education

This event has been pre-approved by:

  • RAPS as eligible for a maximum of 12 credits for a two-day event (appropriate to real-time attendance) towards a participant’s RAC recertification upon full completion.
  • SOCRA who accepts documentation of candidate participation in continuing education programs for re-certification if the program is applicable to clinical research regulations, operations or management, or to the candidate’s clinical research therapeutic area.
  • SQA as eligible for 1 non-GCP or non-GLP unit for every 1 hour of instructional time towards a participant’s RQAP re-registration.
  • ACRP for continuing education in clinical research. ACRP will provide 1 ACRP contact hour for every 45-60 minutes of qualified material.

Questions?

Please refer the FAQs page on this website. If you are not able to find your answer there, please email us at info@sbiaevents.com.

If you have questions regarding the content of the event or other CDER-specific information, please: